Drug intelligence / Profile preview

Esipram

Development stage
Unknown
Lead developer
Dios Lifesciences
Modality
Small Molecules
Administration
Oral
01

Overview

Esipram is a branded generic antidepressant marketed by Dios Lifesciences, containing escitalopram oxalate as its active pharmaceutical ingredient. As a selective serotonin reuptake inhibitor (SSRI), it works by specifically targeting the serotonin transporter (SERT) to inhibit the reuptake of serotonin into the presynaptic neuron, thereby increasing the concentration of the neurotransmitter in the synaptic cleft. This mechanism helps to improve mood and alleviate symptoms of emotional distress. Esipram is primarily indicated for the treatment of major depressive disorder and various anxiety disorders. It is available in oral tablet formulations of 10mg and 20mg.

Brand names
EsipramEsipram-10Esipram10Esipram 10Esipram-20Esipram20Esipram 20
Other names
escitalopram oxalate
02

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on Esipram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esipram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call